

Which lifestyle interventions effectively lower LDL cholesterol?

ELIZABETH POWERS, MD; JOHN SAULTZ, MD; ANDREW HAMILTON, MLS

Oregon Health and Sciences University, Portland

CLINICAL COMMENTARY

Consider patient preference when discussing lifestyle modification

Vincent Lo, MD

San Joaquin Family Medicine Residency, French Camp, Calif

Therapeutic lifestyle changes are the initial treatment of choice for reduction of cardiac risk factors, but both patients and physicians often see these modifications as confusing and difficult to achieve. A recent year-long study on different diets concluded that dietary adherence is more important than a specific type of diet for weight loss and reduction of cardiac risk factors (1). Another recent study reports no difference in weight loss among diets, based on different exercise duration and intensities over 1 year in a group of sedentary and overweight women (2). Therefore, family physicians should consider culture, patient preference, and practical issues such as cost and availability, when discussing therapeutic lifestyle modification with patients.

EVIDENCE-BASED ANSWER

Counseling, weight loss, exercise, and drinking alcohol all effectively lower low-density lipoprotein cholesterol (LDL-C). Specifically, one to two daily drinks of alcohol lowers LDL-C, if consumed regularly for more than 4 weeks (strength of recommendation [SOR]: A, based on consistent results of multiple randomized controlled trials [RCTs]).

Counseling by physicians, dietitians, or pharmacists is effective at increasing patient compliance with medications, thereby lowering LDL-C (SOR: C, good evidence that intervention

lowers LDL-C, insufficient to prove that it reduces mortality/morbidity).

Weight loss has been associated with reductions in LDL-C. However, other factors – including degree of caloric restriction, drug intervention, and diet composition – may play a more significant role than weight loss alone (SOR: A, based on a meta-analysis and consistent results of RCTs).

Exercise significantly lowers LDL-C (SOR: A, based on meta-analyses and consistent results of RCTs). Smoking cessation may have a beneficial effect (SOR: B, based on inconsistent results from RCTs that it lowers LDL-C). Exercise-based alternative practices (yoga and tai chi) lower LDL, and meditation may have a beneficial effect (SOR: C, moderate evidence that intervention lowers LDL, insufficient evidence to prove that it reduces mortality/morbidity).

EVIDENCE SUMMARY

Elevated LDL-C is an independent risk factor for coronary heart disease (CHD), (3) the leading cause of death in the US (4). Lowering LDL-C by 60 mg/dL reduces CHD events by 50% after 2 years (5). Although medications successfully lower LDL-C and decrease CHD risk, therapeutic lifestyle changes remain the initial therapy for most adult patients (3,6).

FAST TRACK

Weight loss lowers LDL-C, although some studies suggest it may be short-term.

Our search located evidence about alcohol consumption, counseling, exercise, weight loss, alternative lifestyle measures, and smoking

LIFESTYLE INTERVENTION	MAGNITUDE OF EFFECT ON LDL-C	% REDUCTION DATA LDL-C	DATA SOURCES	SOR
Alcohol	4-10 mg/dL	4%-8%	4 RCTs	A
Counseling	0-58 mg/dL	0%-33%	15 RCTs, 8 CTs	A
Exercise	3-16 mg/dL	2.5%-4%	5 meta-analysis	A
Meditation	0-28 mg/dL	0%-19%	3 RCTs	B
Smoking	0-5 mg/dL	0%-4%	2 RCTs	B
Weight loss:				
- diet, exercise, supplements	0-42 mg/dL	0%-22%	28 RCTs, 14 CTs, 1 meta-analysis	A
- drug therapy	10-31 mg/dL	11%-32%	4 RCTs, 2 CTs	
Yoga/tai chi	20-26 mg/dL	15%-20%	2 RCTs, 1 CT	A
LDL-C, low-density lipoprotein cholesterol; SOR, strength of recommendation; RCT, randomized controlled trial; CT, clinical trials.				
SOR: A, good evidence that intervention lowers LDL. SOR: B, moderate evidence.				
Table. A- and B-level evidence points to effectiveness of lifestyle interventions				

cessation. The TABLE summarizes the evidence for each.

1 TO 2 DRINKS DAILY REDUCED LDL-C

One 5-year-long cohort study (N=933) showed that alcohol was associated with LDL-C reduction in a dose-dependent manner (7). Two crossover trials (4-6 weeks in duration) conducted among heavy drinkers showed that LDL-C increased when alcohol intake decreased. Two randomized crossover trials (8-12 weeks in duration) found a statistically significant decrease in LDL-C with consumption of 1 to 2 drinks daily.

COUNSELING IMPROVES MEDICATION ADHERENCE

An RCT (N=167) with 8 years of follow-up found that patient education and counseling effectively improved medication adherence (8). Another RCT (N=1162) lasting 1 year, however, found that nutrition counseling by primary care physicians resulted in no significant change in LDL-C compared with usual care (9).

FAST TRACK

2 clinical trials found that LDL decreased significantly with 1 to 2 alcohol drinks per day.

Studies focused on enhancing dietary compliance did not find consistent post-intervention improvement. Greater medication adherence or improved dietary compliance did result in consistent significant improvements in LDL-C.

EXERCISE LOWERS LDL; WEIGHT LOSS A FACTOR

Aerobic exercise effectively lowers LDL-C. This reduction is enhanced by weight loss and diet

and mitigated by weight gain (10). An analysis of 4 RCTs showed that LDL-C also decreased with resistance training.

A higher body-mass index is associated with higher LDL-C. However, the effect of weight loss per se on LDL-C remains unclear. Multiple short-term studies have found that a modest amount of weight loss (5%-10%) is associated with a significant reduction in LDL-C (11). A meta-analysis found a 0.8 mg/dL LDL-C decrease for every kg of weight lost. Long-term follow-up, however, showed that LDL-C returned to baseline even when weight loss was maintained. Eight clinical trials failed to demonstrate a reduction in LDL-C postintervention with up to 10 kg of weight loss. Studies using weight-loss drugs (Sibutramine, Orlistat) found more significant weight loss during treatment, along with greater decrease in LDL-C, when compared with studies using only lifestyle modifications.

OTHER MEASURES HAVE MIXED RESULTS

High-quality RCTs (N=267) with yoga or tai chi as the exercise intervention showed a statistically significant decrease in LDL-C over 12 to 14 weeks (12). Two RCTs investigated the effect of meditation on LDL-C with mixed results. One (N=16) showed a significant decrease in LDL-C over 8 weeks, while a second (N=60) showed no difference in LDL-C. A high-quality RCT (N=91) with a combined intervention (counseling, exercise, and meditation over 1 year) showed a significant decrease in LDL-C.

In cross-sectional surveys, LDL-C does not appear to differ between smokers and non-smokers. One meta-analysis found a dose-dependent relationship between smoking and LDL-C, with overall LDL-C 1.7% higher for

smokers compared with nonsmokers (13). Two RCTs investigated the effect of smoking cessation on LDL-C with mixed results. One (N=935) showed a decrease in non fasting LDL-C while a second (N=140) showed no difference in LDL-C.

RECOMMENDATIONS FROM OTHERS

According to ATP III guidelines, (3) all adults with LDL-C above goal should be treated with therapeutic lifestyle changes for primary and secondary prevention of CHD. These include a diet intervention, increased physical activity, and weight loss. Physicians are encouraged to refer patients to a nutritionist. If LDL-C is not at goal

after 6 weeks, changes are intensified; physicians should consider pharmacologic therapy if a patient is still unable to attain his or her goal. ACP III guidelines recommend an office visit every 4 to 6 months to monitor adherence.

American Heart Association guidelines recommend that physicians counsel smokers at every office visit to stop smoking. The American College of Cardiology recommends abstinence from alcohol for patients with suspected alcoholic cardiomyopathy. For patients with heart failure from any other cause, alcohol consumption is usually limited to 1 drink per day.

REFERENCES

- Dansinger ML, Gleason JA, Griffith JL, et al.** – Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction. *JAMA* 2005; 293:43-53
- Jakicic JM, Marcus BH, Gallagher KL, et al.** – Effect of exercise duration and intensity on weight loss in overweight sedentary women. *JAMA* 2003; 290:1323-1330
- National Cholesterol Education Program Expert Panel on Detection – Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III).** Executive Summary. *JAMA* 2001; 285:2486-2497
- Deaths – Final Data for 2003.** *National Vital Statistics Report* 2003; 54(13). 120pp. (PHS) 2006-1120
- Law MR, Wald NJ, Rudnicka AR** – Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003; 326:1423
- Grundey SM, Cleeman JI, Merz CN, et al.** – National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004; 110:227-239
- Nakanishi N, Yoshida H, Nakamura K, et al.** – Influence of alcohol intake on risk for increased low-density lipoprotein cholesterol in middle-aged Japanese men. *Alcohol Clin Exp Res* 2001; 25:1046-1050.
- Rachmani R, Slavacheski I, Berla M, et al.** – Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. *J Am Soc Nephrol* 2005; 16:S22-S26
- Ockene IS, Hebert JR, Ockene JK, et al.** – Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *Arch Intern Med* 1999; 159:725-731
- Kelley GA, Kelley KS, Tran ZV** – Exercise, lipids, and lipoproteins in older adults: a meta-analysis. *Prev Cardiol* 2005; 8:206-214
- Poobalan A, Aucott L, Smith WC, et al.** – Effects of weight loss in overweight/obese individuals and long-term lipid outcomes: a systematic review. *Obesity Rev* 2004; 5:43-50
- Tsai JC, Wang WH, Chan P, et al.** – The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. *J Altern Complement Med* 2003; 9:747-754
- Craig WY, Palomaki GE, Haddow JE** – Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *Br Med J* 1989; 298:784-788
- program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus.** *J Alt Complement Med* 2005; 11:267-274
- Tsai JC, et al.** – The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. *J Alt Complement Med* 2003; 9:747-754
- Mahajan AS, Reddy KS, Sachdeva U** – Lipid profile of coronary risk subjects following yogic lifestyle intervention. *Indian Heart J* 1999; 51:37-40
- Carson MA** – The impact of a relaxation technique on the lipid profile. *Nurs Res* 1996; 45:271-276
- Jula A, et al.** – Long-term non-pharmacological treatment for mild to moderate hypertension. *J Intern Med* 1990; 227:413-421
- Carson MA, et al.** – The effect of a relaxation technique on coronary risk factors. *Behav Med* 1988; 14:71-77

ADDITIONAL REFERENCES ALTERNATIVE LIFESTYLE

PRACTICES

- Bijlani RL, et al.** – A brief but comprehensive lifestyle education

ALCOHOL

- Coimbra SR, et al.** – The action of red wine and purple grape juice on vascular reactivity is independent of plasma lipids in hypercholesterolemic patients. *Brazilian J Med Biol Res* 2005; 38:1339-1347
- Hansen AS, et al.** – Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. *Eur J Clin Nutr* 2005; 59:449-455
- Chrysohoou C, et al.** – Effects of chronic alcohol consumption on lipid levels, inflammatory and

- haemostatic factors in the general population: the 'ATTICA' study. *Eur J Cardiovasc Prev Rehabil* 2003; 10:355-361
4. **Dixon JB, Dixon ME, O'Brien PE** – Alcohol consumption in the severely obese: relationship with the metabolic syndrome. *Obes Res* 2002; 10:245-252
 5. **Baer DJ, et al.** – Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet. *Am J Clin Nutr* 2002; 75:593-599
 6. **Nakanishi N, et al.** – Influence of alcohol intake on risk for increased low-density lipoprotein cholesterol in middle-aged Japanese men. *Alcohol Clin Exp Res* 2001; 25:1046-1050
 7. **Senault C, et al.** – Beneficial effects of a moderate consumption of red wine on cellular cholesterol efflux in young men. *Nutr Metab Cardiovasc Dis* 2000; 10:63-69
 8. **Rakic V, et al.** – A controlled trial of the effects of pattern of alcohol intake on serum lipid levels in regular drinkers. *Atherosclerosis* 1998; 137:243-252
 9. **Kiechl S, et al.** – Alcohol consumption and atherosclerosis: what is the relation? Prospective results from the Bruneck Study. *Stroke* 1998; 29:900-907
 10. **Hein HO, Suadicani P, Gyntelberg F** – Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. *BMJ* 1996; 312:736-741
 11. **Clevidence BA, et al.** – Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study. *Arterioscler Thromb Vasc Biol* 1995; 15:179-184
 12. **Sharpe PC, et al.** – Effect of red wine consumption on lipoprotein (a) and other risk factors for atherosclerosis. *QJM* 1995; 88:101-108
 13. **Masarei JR, et al.** – Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Results from an intervention study in healthy subjects. *Atherosclerosis* 1986; 60:79-87
 3. **Levetan CS, et al.** – Impact of computer-generated personalized goals on cholesterol lowering. *Value Health* 2005; 8:639-646
 4. **Rachmani R, et al.** – Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. *J Am Soc Nephrol* 2005; 16:S22-S26
 5. **Burke LE, et al.** – Improving adherence to a cholesterol-lowering diet: a behavioral intervention study. *Patient Educ Couns* 2005; 57:134-142
 6. **Lee SS, Cheung PY, Chow MS** – Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. *J Clin Pharmacol* 2004; 44:632-639
 7. **Simpson DR, Dixon GB, Bolli P** – Effectiveness of multidisciplinary patient counseling in reducing cardiovascular disease risk factors through nonpharmacological intervention: results from the Healthy Heart Program. *Can J Cardiol* 2004; 20:177-186
 8. **Lichtman JH, et al.** – Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. *Am Heart J* 2004; 147:522-528
 9. **Thomas HD, Maynard C, Wagner GS** – Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. *N C Med J* 2003; 64:263-266
 10. **Reid R, et al.** – Dietary counseling for dyslipidemia in primary care: results of a randomized trial. *Can J Pract Res* 2002; 63:169-175
 11. **Palomaki A, et al.** – Effects of preventive group education on the resistance of LDL against oxidation and risk factors for coronary heart disease in bypass surgery patients. *Ann Med* 2002; 34:272-283
 12. **Vale MJ, et al.** – Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world" – randomized controlled trial. *J Clin Epidemiol* 2002; 55:245-252
 13. **Cabrera-Pivaral CE, et al.** – Effects of an educational intervention on plasma levels of LDL cholesterol in type 2 diabetics. *Salud Publica Mex* 2001; 43:556-562
 14. **Henkin Y, et al.** – Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized, controlled trial. *Am J Med* 2000; 109:549-555
 15. **Faulkner MA, et al.** – Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. *Pharmacotherapy* 2000; 20:410-416
 16. **Hines L** – Can low-fat/cholesterol nutrition counseling improve food intake habits and hyperlipidemia of renal transplant patients? *J Ren Nutr* 2000; 10:30-35
 17. **Hebert JR, et al.** – A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *J Am Diet Assoc* 1999; 99:544-552
 18. **Allison TG, et al.** – Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. *Mayo Clin Proc* 1999; 74:466-473
 19. **Ockene IS, et al.** – Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyper-lipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *Arch Intern Med* 1999; 159:725-731
 20. **Verges BL, et al.** – Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. *J Cardiopulm Rehabil* 1998; 18:408-415
 21. **Keyserling TC, et al.** – A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project. *Arch Fam Med* 1997; 6:135-145
 22. **Johnston HJ, et al.** – Diet modification in lowering plasma cholesterol levels. A randomized trial of three types of intervention. *Med J Aust* 1995; 162:524-526
 23. **Anderson JW, Brinkman VL, Hamilton CC** – Weight loss and 2-year follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program. *Am J Clin Nutr* 1992; 56:244S-246S
 24. **Rabkin SW, et al.** – A randomized clinical trial comparing behavior modification and individual counseling in the nutritional therapy of non-insulin-dependent diabetes mellitus: comparison of the effect on blood sugar, body weight, and serum lipids. *Diabetes Care* 1983; 6:50-56

EXERCISE

1. **Kelley GA, Kelley KS, Tran ZV** – Exercise, lipids, and lipoproteins in

- older adults: a meta-analysis. *Prev Cardiol* 2005; 8:206-214
2. **Kelley GA, Kelley KS, Tran ZV** – Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. *J Womens Health* 2004; 13:1148-1164
 3. **Halbert JA, et al.** – Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. *Eur J Clin Nutr* 1999; 53:514-522
 4. **Yu-Poth S, et al.** – Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999; 69:632-646
 5. **Tran ZV, Weltman A** – Differential effects of exercise on serum lipid and lipoprotein levels seen with changes in body weight. A meta-analysis. *JAMA* 1985; 254:919-924

SMOKING

1. **Allen SS, Hatsukami D, Gorsline J** – Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. *Prev Med* 1994; 23:190-196
2. **Hughes K, et al.** – Relationships between cigarette smoking, blood pressure and serum lipids in the Singapore general population. *Int J Epidemiol* 1993; 22:637-643
3. **Vyssoulis GP, et al.** – Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. *Am J Cardiol* 1991; 67:987-992
4. **Cuesta C, et al.** – Effects of age and cigarette smoking on serum concentrations of lipids and apolipoproteins in a male military population. *Atherosclerosis* 1989; 80:33-39
5. **Craig WY, Palomaki GE, Haddow JE** – Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ* 1989; 298:784-788
6. **Rabkin SW** – Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A controlled clinical trial. *Atherosclerosis* 1984; 53:173-184
7. **Halfon ST, Green MS, Heiss G** – Smoking status and lipid levels in adults of different ethnic origins: the Jerusalem Lipid Research Clinic Program. *Int J Epidemiol* 1984; 13:17-183
8. **Brischetto CS, et al.** – Plasma lipid and lipoprotein profiles of cigarette smokers from randomly selected families: enhancement of hyperlipidemia and depression of high-density lipoprotein. *Am J Cardiol* 1983; 52:675-680
9. **Sutherland WH, et al.** – Adiposity, lipids, alcohol consumption, smoking, and gender. *Am J Clin Nutr* 1980; 33:2581-2587
10. **Heyden S, et al.** – The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. *Circulation* 1979; 60:22-25

WEIGHT LOSS

1. **Wood RJ, et al.** – Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL sub-fraction distribution and size in overweight men. *J Nutr* 2006; 136:384-389
2. **Lofgren I, et al.** – Weight loss associated with reduced in-take of carbohydrate reduces the atherogenicity of LDL in premenopausal women. *Metabolism* 2005; 54:1133-1141
3. **LaHaye SA, et al.** – Comparison between a low glycemic load diet and a Canada Food Guide diet in cardiac rehabilitation patients in Ontario. *Can J Cardiol* 2005; 21:489-494
4. **Zemel MB, et al.** – Dairy augmentation of total and central fat loss in obese subjects. *Int J Obes* 2005; 29:391-397
5. **Fernandez ML, et al.** – Beneficial effects of weight loss on plasma apolipoproteins in post-menopausal women. *J Nutr Biochem* 2004; 15:717-721
6. **Zaffari D, et al.** – Effectiveness of diet in hyperlipidemia in renal transplant patients. *Transplant Proc* 2004; 36:889-890
7. **Erdmann J, et al.** – Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. *Aliment Pharmacol Ther* 2004; 19:1173-1179
8. **Yancy WS Jr, et al.** – A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. *Ann Int Med* 2004; 140:769-777
9. Four popular diets all good for weight loss but not equal for reducing heart disease risk *SAMJ* 2004; 94:161
10. **Brook RD, et al.** – Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. *Am J Cardiol* 2004; 93:1012-1016
11. **Poobalan A, et al.** – Effects of weight loss in overweight/obese individuals and long-term lipid outcomes—a systematic review. *Obes Rev* 2004; 5:43-50
12. **Ley SJ, et al.** – Long-term effects of a reduced fat diet intervention on cardiovascular disease risk factors in individuals with glucose intolerance. *Diabetes Res Clin Pract* 2004; 63:103-112
13. **Lovejoy JC, et al.** – Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study. *Int J Obes Relat Metab Disord* 2003; 27:1242-1249
14. **Bergholm R, et al.** – Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilation in obese women with previous gestational diabetes. *Diabetes Care* 2003; 26:1667-1672
15. **Melanson K, et al.** – Weight loss and total lipid profile changes in overweight women consuming beef or chicken as the primary protein source. *Nutrition* 2003; 19:409-414
16. **Allison DB, et al.** – A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. *Eur J Clin Nutr* 2003; 57:514-522
17. **Lucas CP, Boldrin MN, Reaven GM** – Effect of orlistat added to diet (30% calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. *Am J Cardiol* 2003; 91:961-964
18. **Reid R, et al.** – Dietary counseling for dyslipidemia in primary care: results of a randomized trial. *Can J Diet Pract Res* 2002; 63:169-175
19. **Boozer CN, et al.** – Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *Int J Obes Relat Metab Disord* 2002; 26:593-604
20. **Parker B, et al.** – Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. *Diabetes Care* 2002; 25:425-430
21. **Delahanty LM, et al.** – Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. *J Am Diet Assoc* 2001; 101:1012-1023
22. **Ashley JM, et al.** – Weight control in the physician's office. *Arch Intern Med* 2001; 161:1599-1604
23. **Shintani TT, et al.** – The Hawaii Diet: ad libitum high carbohydrate, low fat multi-cultural diet for the reduction of chronic disease risk factors: obesity, hypertension, hypercholesterolemia, and hyperglycemia. *Hawaii Med J* 2001; 60:69-73
24. **Raeini-Sarjaz M, et al.** – Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism. *Am J Clin Nutr* 2001; 73:262-267
25. **Manley SE, et al.** – Effects of three months' diet after diagnosis of Type

- 2 diabetes on plasma lipids and lipoproteins. *Diabetes Med* 2000; 17:518-523
26. **Cordero-MacIntyre ZR, et al.** – Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. *J Am Coll Nutr* 2000; 19:275-284
27. **Noakes M, Clifton PM** – Weight loss and plasma lipids. *Curr Opin Lipidol* 2000; 11:65-70
28. **Purnell JQ, et al.** – Effect of weight loss with reduction of intraabdominal fat on lipid metabolism in older men. *J Clin Endocrinol Metab* 2000; 85:977-982
29. **Zambon A, et al.** – Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women. *J Intern Med* 1999; 246:191-201
30. **Di Buono M, et al.** – Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. *J Nutr* 1999; 129:1545-1548
31. **Herbert JR, et al.** – A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *J Am Diet Assoc* 1999; 99:544-552
32. **Yu-Poth S, et al.** – Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999; 69:632-646
33. **Bray GA, et al.** – Sibutramine produces dose-related weight loss. *Obes Res* 1999; 7:189-198
34. **Wadden TA, Anderson DA, Foster GD** – Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. *Obes Res* 1999; 7:170-178
35. **Turley ML, et al.** – The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. *Eur J Clin Nutr* 1998; 52:728-732
36. **Butowski PF, Winder AF** – Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolemia. Data from the U.K. Lipid Clinics Programme. *Eur Heart J* 1998; 19:1328-1333
37. **Stefanick ML, et al.** – Effects of diet and exercise in men and postmenopausal women with low level HDL cholesterol and high levels of LDL cholesterol. *N Engl J Med* 1998; 339:12-20
38. **St Jeor ST, et al.** – A classification system to evaluate weight maintainers, gainers, and losers. *J Am Diet Assoc* 1997; 97:481-488
39. **Muls E, et al.** – Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates. *Int J Obes Relat Metab Disord* 1997; 21:155-158
40. **McCarron DA, et al.** – Nutritional management of cardiovascular risk factors. A randomized clinical trial. *Arch Intern Med*. 1997; 157:169-177
41. **Fox AA, et al.** – Effects of diet and exercise on common cardiovascular disease risk factors in moderately obese older women. *Am J Clin Nutr* 1996; 63:225-233
42. **Pascale RW, et al.** – Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. *Diabetes Care* 1995; 18:1241-1248
43. **Schaefer EJ, et al.** – Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. *JAMA* 1995; 274:1450-1455
44. **Andersen RE, et al.** – Relation of weight loss to changes in serum lipids and lipoproteins in obese women. *Am J Clin Nutr* 1995; 62:350-357
45. **Wing RR, Jeffery RW** – Effect of modest weight loss on changes in cardiovascular risk factors; are there difference between men and women or between weight loss and maintenance? *Int J Obes Relat Metab Disord* 1995; 19:67-73
46. **Svendsen OL, Hassager C, Christiansen C** – Six months' follow-up on exercise added to a short-term diet in overweight postmenopausal women—effects on body composition, resting metabolic rate, cardiovascular risk factors and bone. *Int J Obes Relat Metab Disord* 1994; 18:692-698
47. **Svendsen OL, Hassager C, Christiansen C** – Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. *Am J Med* 1993; 95:131-140
48. **Datillo AM, Kris-Etherton PM** – Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992; 56:320-328
49. **Wolever TM, et al.** – Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. *Diabetes Care* 1992; 15:562-564
50. **Anderson JW, Brinkman VL, Hamilton CC** – Weight loss and 2-year follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program. *Am J Clin Nutr* 1992; 56:244S-246S
51. **Williams PT, et al.** – Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. *Arteriosclerosis* 1989; 9:623-632
52. **Wood PD, et al.** – Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 1988; 319:1173-1179
53. **Hagan RD, et al.** – The effects of aerobic conditioning and/or caloric restriction in overweight men and women. *Med Sci Sports Exerc* 1986; 18:87-94
54. **Walsh DE, Yaghoubian V** – Effect of glucomannan on obese patients: a clinical study. *Int J Obes* 1984; 8:289-293

©2007, Dowden Health Media, Inc. All rights reserved. This article was reprinted from the original article published in the *Journal of Family Practice*, June 2007, Vol. 56, No. 6, pp 483-489. A publication of Dowden Health Media, Inc.

Vizitați site-ul

SOCIETĂȚII ACADEMICE DE MEDICINĂ A FAMILIEI

www.samf.ro